Peptides
NA-Semax amidate: modified peptide, untested claims
What is it?
NA-Semax amidate is a version of Semax with an N-terminal acetyl group and a C-terminal amide. These modifications are marketed as improving stability or potency, but those properties require direct measurement; a chemical rationale is not a clinical result. [1]
What do studies show?
A small Russian clinical report studied unmodified Semax in 30 patients after ischemic stroke against a nonrandomized conventional-care comparison group. That setting is far removed from healthy-person focus or memory enhancement. Neither it nor other parent-Semax work establishes benefits for the N-acetyl amidate analogue. We did not identify a controlled human study of the exact modified molecule. [2,3]
Safety
The effects of modifying both ends of the peptide on absorption, adverse events, and duration are not established in people. FDA’s evaluation of Semax-related bulk substances highlights uncertainty about product quality and peptide-related risks; it does not validate the modified catalogue product. [3]
DOSE STATUS
How much?
EVIDENCE CONTEXT
Why?
The cited evidence does not establish a dose for this use or product.
No safe and effective adult dose of NA-Semax amidate has been established. Anecdotal amounts for plain Semax are not interchangeable with this analogue. The catalog vial amount gives no route, exposure, or safety basis, and no well-attributed exact-form protocol was identified. [1,3]